Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Reporting Period: Quarter ended September 30, 2024 (Q3 2024)
Business Overview: A discovery and development-stage pharmaceutical company focused on cancer immunotherapies, specifically radiation sensitizers (Ropidoxuridine) and HDAC inhibitors. The company is currently conducting a Phase II clinical trial for Ropidoxuridine in glioblastoma patients.
Capital Structure Event: A 1-for-8 reverse stock split was effectuated on August 13, 2024, to meet Nasdaq minimum bid price requirements. All share data is presented on a post-split basis.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(3,784,082) | $(1,792,754) | $(7,546,328) | $(4,952,223) |
| Loss Per Share (Basic/Diluted) | $(1.59) | $(0.91) | $(3.45) | $(2.72) |
| Cash and Cash Equivalents (End of Period) | $156,656 | $3,885,997 | $156,656 | $3,885,997 |
| Working Capital | $(1,297,882) | $4,550,768 | $(1,297,882) | $4,550,768 |
| Stockholders' Equity (Deficit) | $(1,315,377) | $5,609,749 | $(1,315,377) | $5,609,749 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased 91% in Q3 2024 compared to Q3 2023, driven primarily by a 358% increase in legal and professional fees ($1.32M vs $0.29M) due to reaudits, public filing requirements, and financing activities. R&D expenses increased 34% to $1.4M.
- Liquidity Position: Cash and cash equivalents declined significantly from $2.58M at year-end 2023 to $156,656 at September 30, 2024. The company moved from a working capital surplus of $4.55M in 2023 to a deficit of $1.3M in 2024.
- Debt Settlement: The company recognized a loss on settlement of convertible debt of $762,186 in Q3 2024, compared to $43,414 in the prior year quarter, as debt was settled via common stock issuance.
- Derivative Liabilities: The fair value of derivative liabilities decreased from $414,512 at year-end 2023 to $74,107 at September 30, 2024, resulting in a non-cash gain of $286,316 in Q3 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. Existing cash and recent financing are insufficient to fund operations and clinical trials through the next year without additional capital.
- Recent Financing (Subsequent Events): In October 2024, the company raised approximately $4.7M total: $790,000 via senior secured convertible bridge notes and $3.9M net cash via an equity offering (shares and pre-funded warrants).
- Clinical Progress: The Phase II clinical trial for Ropidoxuridine has enrolled its first three patients as of October 2024. The FDA recommended an expansion of the trial, requiring additional capital.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum stockholders' equity requirement ($2.5M). A plan to regain compliance was submitted in October 2024, but delisting remains a risk if compliance is not achieved.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2024, citing material weaknesses in accounting policies, segregation of duties, and financial reporting oversight.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.7M raised in October 2024 to cover the expanded Phase II trial costs and operating burn rate for the next 12 months.
- Nasdaq Status: Monitor the acceptance of the compliance plan and the company's ability to restore stockholders' equity above $2.5M to avoid delisting.
- Debt Obligations: Review the terms of the new senior secured convertible notes (14.5% interest, 5% OID) and the potential for further dilution via conversion or warrant exercises.
- Internal Controls: Assess the progress of remediation efforts regarding the identified material weaknesses in financial reporting and the impact on future filing timeliness.
- Clinical Milestones: Track patient enrollment rates in the Phase II trial and any FDA communications regarding the trial expansion.